Suchergebnisse - "9NDF7JZ4M3"

PubPharm (4.971)

4951

Prevention and treatment of experimental thrombosis in rabbits with rivaroxaban (BAY 597939)--an oral, direct factor Xa inhibitor

enthalten in: Thrombosis and haemostasis | 2007

von Biemond, B. | Perzborn, E. | Friederich, P. | +3

4952

Drug evaluation : rivaroxaban, an oral, direct inhibitor of activated factor X

enthalten in: Current opinion in investigational drugs (London, England : 2000) | 2007

von Kakar, P. | Watson, T. | Lip, G.

4953

Dose-escalation study of rivaroxaban (BAY 59-7939)--an oral, direct Factor Xa inhibitor--for the prevention of venous thromboembolism in patients undergoing total hip replacement

enthalten in: Thrombosis research | 2007

von Eriksson, B. | Borris, L. | Dahl, O. | +6

4954

Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects

enthalten in: Journal of clinical pharmacology | 2007

von Kubitza, D. | Becka, M. | Zuehlsdorf, M. | +1

ErratumIn: J Clin Pharmacol. 2008 Nov;48(11):1366-7

4955

A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement

enthalten in: Circulation | 2006

von Eriksson, B. | Borris, L. | Dahl, O. | +8

CommentIn: Circulation. 2006 Nov 28;114(22):2313-6. - PMID 17130355

4956

The scientific community's quest to identify optimal targets for anticoagulant pharmacotherapy

enthalten in: Circulation | 2006

von Mahaffey, K. | Becker, R.

CommentOn: Circulation. 2006 Nov 28;114(22):2374-81. - PMID 17116766

4957

Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban--an oral, direct factor Xa inhibitor--are not affected by aspirin

enthalten in: Journal of clinical pharmacology | 2006

von Kubitza, D. | Becka, M. | Mueck, W. | +1

4958

Novel factor Xa inhibitors for prevention and treatment of thromboembolic diseases

enthalten in: Expert opinion on investigational drugs | 2006

von Kubitza, D. | Haas, S.

4959

Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59-7939 (rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects

enthalten in: Journal of clinical pharmacology | 2006

von Kubitza, D. | Becka, M. | Zuehlsdorf, M. | +1

4960

New oral anticoagulants show promise

enthalten in: JAMA | 2006

von Hampton, T.